The Marfan database is a software that contains routines for the analysis of mutations identified in the FBN1 gene that encodes fibrillin-1. Mutations in this gene are associated not only with Marfan syndrome but also with a spectrum of overlapping disorders. The third version of the Marfan database contains 137 entries. The software has been modified to accommodate four new routines and is now accessible on the World Wide Web at http://www.umd.necker.fr
FIBRILLIN, MARFAN SYNDROME AND TYPE 1 FIBRILLINOPATHIES
Fibrillin-1 is the principal structural element of a class of connective tissue microfibrils that have a widespread distribution (1) . In elastic tissues, fibrillin microfibrils play a key role in elastic fibrillogenesis and are components of elastic fibers which generate elastic recoil (2, 3) . In non-elastic tissues, they are proposed to play an anchoring role (4) . Fibrillin-1 is encoded by a relatively large and fragmented gene (65 exons distributed over ∼110 kb) located at 15q15-q21.1 (5) (6) (7) (8) . It has a complex multi-domain structure comprising 47 epidermal growth factor (EGF)-like modules (43 of which have a calcium-binding consensus sequence) interspersed with seven '8-cysteine' repeats with homology to the TGF-β1 binding protein and two 'hybrid' modules.
Marfan syndrome (MFS) is an autosomal dominant disorder affecting mainly the cardiovascular, skeletal and ocular systems (9) . The reported incidence is at least 1 per 10 000 with >25% of cases being the result of new mutations. The disease is associated with mutations in the gene encoding fibrillin-1 (FBN1 The columns contain the following information and abbreviations: A: Report number. B: Exon number at which the mutation is located. C: Nucleotide position at which the mutation is located, numbered with respect to the FBN1 gene cDNA sequence obtained from GenBank (GenBank accession number L13923; complete coding sequence of HUM-FIBRILLIN Homo sapiens fibrillin mRNA). D: Codon number at which the mutation is located. E: Normal base sequence of the codon in which the mutation occured. F: Mutated base sequence of the codon in which the mutation occured. G: Concerns base substitutions. It gives the base change, by convention, read from the coding strand. If the mutation predicts a premature protein-termination, the novel stop codon position is given, e.g. Stop at 2115. 
THE MARFAN DATABASE
The mutations file of the database lists point mutations, deletions or insertions, and splice mutations in the FBN1 gene (Table 1) . It contains in a standarized, easily accessible and summary form the molecular and the clinical data on the causative mutations of Marfan syndrome and type 1 fibrillinopathies. For each mutation, information is provided at several levels: at the gene level (exon and codon number, wild type and mutant codon, mutational event, mutation name), at the protein level (wild type and mutant amino acid, affected domain) and at the clinical level (absence or presence of skeletal, ocular, cardiovascular, central nervous system and other various manifestations). The present version of the database contains 137 entries corresponding to mutations either recently published or only reported in meeting proceedings or contributed by the co-authors of this paper. It is not intented to replace primary publications, although it does contain unpublished data. Forty eight new entries appear, as compared to the last update.
ANALYSIS AND LIMIT OF THE DATABASE
The global molecular analysis of the mutations file reveals that nonsense mutations (7/137), splicing errors (18/137) and small deletions (12/137) predicted to result in truncated fibrillin-1 molecules have been identified but represent a small proportion of the mutations. Insertions are surprisingly under-represented (2/137). The majority of mutations identified are missense mutations (99/137 or 72.3%) affecting primarily (73/99) the numerous calcium binding (EGF)-like modules found throughout the protein. The fibrillin gene has been identified and sequenced in two mammalian species. The identity at the amino acid level is so high (97.8% human-mouse and 96.2% human-bovine) that very often phylogenic conservation should be observed at the amino acid position affected by a given missense mutation. In effect, in all the mutations thus far reported in the FBN1 gene, the mutational event affects a conserved amino acid with respect to the mouse and bovine sequences. It is interesting to note that the only exception is the Y2113X mutation (which affects a non-conserved amino acid) leads to a truncated protein. The mutations file contains 11 recurrent mutations that have been reported either twice (R122C, R545C, R627C, C1117Y, R1137P, R1170H, C1223Y and R2282W) or thrice (G1013R, E1073K and 5788+5G→A). Until haplotype analysis is available it is unclear whether these are truly recurrent mutations or if they are carried by the same chromosome.
There is an excess of mutations in exons 25, 27 and 28 (P < 0.001) when comparing observed to expected mutations. This clustering is explained by the fact that almost all the mutations identified in neonatal cases of MFS1 are located within this area.
Since the present version of the software cannot accomodate two mutational events in a given individual, three mutations are not included in the current version of the mutations file: the double mutant Splice exon 51 and X2113X reported by Dietz et al. (12) , the compound deletion del3901-4; 3908-9 reported by Nijbroek et al. (13) , and the double mutant I1071S and E1073D reported by Wang et al. (14) . Three other mutations are not included in the Marfan database [1588+21G→A (15) , 2294-1G→C and 1837+5G→A (NP1)] until more precise information is available on mRNA splicing or stability. All things considered, 143 mutations have been described to date in the FBN1 gene.
NEW WEB VERSION OF THE SOFTWARE AND ITS NEWLY DEVELOPED ROUTINES
Four new routines now appear in the Marfan database as follows. The software is now accessible through the World Wide Web and analyses with the various routines can be performed by users on-line. The investigation of genotype/phenotype correlations with these tools is currently difficult since clinical data is often sparse in mutation records. To facilitate the input of high quality clinical data, we are currently developing a Mutation Report Entry in the web site.
DATABASE UPDATE, SOFTWARE AVAILABILITY AND ONLINE ANALYSIS
The current database and subsequent updated versions are available on request to G.C-B. or C.Boileau on floppy disc using Apple format and Microsoft ExcelR, or by Email (collod@ ceylan.necker.fr). Notification of omissions and errors in the current version as well as specific phenotypic data would be gratefully received by the corresponding author. The software package is available on a collaborative basis. The software will be expanded as the database grows and according to the requirements of its users. New functions could be implemented. New web version of the Marfan Database permitting on-line analysis is accessible at http://www.umd.necker.fr . Users of the database must cite this article.
